Burzynski Research Institute Inc (BZYR) Financial Statements (2024 and earlier)

Company Profile

Business Address 12000 RICHMOND AVE
HOUSTON, TX 77082
State of Incorp. DE
Fiscal Year End February 28
Industry (SIC) 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

8/31/2023
MRQ
2/28/2023
11/30/2022
MRQ
2/28/2022
2/28/2021
2/29/2020
2/28/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments9341,6923,38262163708
Cash and cash equivalents9341,6923,38262163708
Prepaid expense1,0001001,27989419,69021,464
Total current assets:1,9341,7924,66195619,85322,172
Noncurrent Assets
TOTAL ASSETS:1,9341,7924,66195619,85322,172
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities15,66128,4203,45546,799172,440208,820
Accounts payable 12,57016,650 32,51260,805101,065
Accrued liabilities3,09111,7703,45514,287111,635107,755
Total current liabilities:15,66128,4203,45546,799172,440208,820
Noncurrent Liabilities
Total liabilities:15,66128,4203,45546,799172,440208,820
Equity
Equity, attributable to parent(13,727)(26,628)1,206(45,843)(152,587)(186,648)
Common stock131,449131,449131,449131,449131,449131,449
Additional paid in capital126,609,599126,380,700125,708,240124,684,535123,373,793121,705,250
Accumulated deficit(126,754,775)(126,538,777)(125,838,483)(124,861,827)(123,657,829)(122,023,347)
Total equity:(13,727)(26,628)1,206(45,843)(152,587)(186,648)
TOTAL LIABILITIES AND EQUITY:1,9341,7924,66195619,85322,172

Income Statement (P&L) (USD)

8/31/2023
TTM
2/28/2023
11/30/2022
TTM
2/28/2022
2/28/2021
2/29/2020
2/28/2019
Operating expenses(916,292)(626,115)(976,656)(1,301,771)(1,634,982)(1,637,717)
Operating loss:(916,292)(626,115)(976,656)(1,301,771)(1,634,982)(1,637,717)
Nonoperating income
(Other Nonoperating income)
    97,773500 
Loss from continuing operations:(916,292)(626,115)(976,656)(1,203,998)(1,634,482)(1,637,717)
Loss before gain (loss) on sale of properties:(373,476)(976,656)(1,203,998)(1,634,482)(1,637,717)
Net loss available to common stockholders, diluted:(916,292)(626,115)(976,656)(1,203,998)(1,634,482)(1,637,717)

Comprehensive Income (USD)

8/31/2023
TTM
2/28/2023
11/30/2022
TTM
2/28/2022
2/28/2021
2/29/2020
2/28/2019
Net loss:(916,292)(626,115)(976,656)(1,203,998)(1,634,482)(1,637,717)
Comprehensive loss, net of tax, attributable to parent:(916,292)(626,115)(976,656)(1,203,998)(1,634,482)(1,637,717)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: